Work

P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers

Year: 2017

Type: article

Study design: Clinical Trial

Source: Journal of Crohn s and Colitis

DOI: 10.1093/ecco-jcc/jjx002.494

Authors: L. Peyrin-Biroulet, R. Christopher, L. Trokan, C. Lassen, J. Adams, T. Kühbacher

Institutions: Centre Hospitalier Régional et Universitaire de Nancy, Université de Lorraine, Arena Pharmaceuticals (United States), Christian-Albrechts-Universität zu Kiel, Asklepios

Language: English

Topic: Sphingolipid Metabolism and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2586099691

FWCI: 0.223

Cites:

Cited by: 4

Related to: 10